{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:33:22Z","timestamp":1791113602080,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":4176,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1111\/j.1523-1755.2004.00701.x","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T14:16:26Z","timestamp":1086790586000},"page":"1-9","source":"Crossref","is-referenced-by-count":217,"title":["Aldosterone in the development and progression of renal injury"],"prefix":"10.1016","volume":"66","author":[{"given":"Norman K.","family":"Hollenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0010","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0015","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0140-6736(52)91551-1","article-title":"Secretion of a salt-retaining hormone by the mammalian adrenal cortex","volume":"263","author":"Simpson","year":"1952","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0020","first-page":"3","article-title":"Presidential address. Part II: Primary aldosteronism: A new clinical syndrome","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0002-9610(64)90252-1","article-title":"Clinical characteristics of primary aldosteronism from an analysis of 145 cases","volume":"107","author":"Conn","year":"1964","journal-title":"Am J Surg"},{"issue":"Suppl","key":"10.1111\/j.1523-1755.2004.00701.x_bb0030","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1097\/00005344-199212001-00010","article-title":"Myocardial fibrosis and the renin-angiotensin-aldosterone system","volume":"20","author":"Weber","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0035","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/cvr\/28.12.1863","article-title":"Aldosterone and cardiac fibrosis: In vitro studies","volume":"28","author":"Fullerton","year":"1994","journal-title":"Cardiovasc Res"},{"issue":"3 Pt 1","key":"10.1111\/j.1523-1755.2004.00701.x_bb0040","doi-asserted-by":"crossref","first-page":"C421","DOI":"10.1152\/ajpcell.1990.259.3.C421","article-title":"Role of protein kinase C in renal vasoconstriction caused by angiotensin II","volume":"259","author":"Scholz","year":"1990","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1172\/JCI113092","article-title":"Angiotensin II\u2014noradrenergic interactions in renovascular hypertensive rats","volume":"80","author":"Zimmerman","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0050","first-page":"423","article-title":"Regulation of proximal tubule transport by angiotensin II","volume":"17","author":"Quan","year":"1997","journal-title":"Semin Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0055","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0060","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1046\/j.1440-1681.2001.03586.x","article-title":"Mineralocorticoids and cardiac fibrosis: The decade in review","volume":"28","author":"Funder","year":"2001","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0065","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0039-128X(94)00026-9","article-title":"Aldosterone biosynthesis and action in vascular cells","volume":"60","author":"Takeda","year":"1995","journal-title":"Steroids"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0303-7207(02)00041-2","article-title":"Steroidogenic enzyme gene expression in the human brain","volume":"190","author":"Yu","year":"2002","journal-title":"Mol Cell Endocrinol"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0075","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1006\/frne.1997.0157","article-title":"Central hypertensive effects of aldosterone","volume":"18","author":"Gomez-Sanchez","year":"1997","journal-title":"Front Neuroendocrinol"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0080","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1161\/01.CIR.90.4.1883","article-title":"Arterial baroreflex control of renal hemodynamics in humans","volume":"90","author":"Van Tilborg","year":"1994","journal-title":"Circulation"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0085","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/01.HYP.19.3.270","article-title":"Aldosterone reduces baroreceptor discharge in the dog","volume":"19","author":"Wang","year":"1992","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0090","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.HYP.37.2.787","article-title":"Mineralocorticoid receptor affects AP-1 and nuclear factor-kappaB activation in angiotensin II-induced cardiac injury","volume":"37","author":"Fiebeler","year":"2001","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0095","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1210\/endo.141.5.7529","article-title":"Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy","volume":"141","author":"Takeda","year":"2000","journal-title":"Endocrinology"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0100","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1161\/01.CIR.102.12.1342","article-title":"Targeting pathological remodeling. Concepts of cardioprotection and reparation","volume":"102","author":"Weber","year":"2000","journal-title":"Circulation"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/01.RES.37.1.101","article-title":"Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat","volume":"37","author":"Myers","year":"1975","journal-title":"Circ Res"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0344-0338(82)80017-4","article-title":"The compensated and the decompensated form of benign nephrosclerosis","volume":"174","author":"Bohle","year":"1982","journal-title":"Pathol Res Pract"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0115","first-page":"741","article-title":"Stroke-prone renovascular hypertensive rats","volume":"111","author":"Zeng","year":"1998","journal-title":"Chin Med J (Engl"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0002-9343(85)90078-6","article-title":"Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model","volume":"79","author":"Raij","year":"1985","journal-title":"Am J Med"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0125","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1172\/JCI112528","article-title":"Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat","volume":"77","author":"Anderson","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0130","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ki.1987.62","article-title":"Reversing glomerular hypertension stabilizes established glomerular injury","volume":"31","author":"Meyer","year":"1987","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0135","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJM198512263132601","article-title":"Effect of captopril on heavy proteinuria in azotemic diabetics","volume":"313","author":"Taguma","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0140","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archinte.1995.00430100105012","article-title":"Long-term effects of antihypertensive agents on proteinuria and renal function","volume":"155","author":"Maki","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0145","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0150","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","author":"Gisen Group","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0155","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0160","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0165","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0170","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0175","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0180","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/ki.1992.45","article-title":"Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level","volume":"41","author":"Quan","year":"1992","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0185","first-page":"F286","article-title":"Characterization of renal aldosterone receptors in genetically hypertensive rats","volume":"264","author":"Horiuchi","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0190","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0195","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0200","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: A mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0205","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJM199405193302008","article-title":"The emerging concept of vascular remodeling","volume":"330","author":"Gibbons","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0210","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00060793-199806000-00011","article-title":"Nonepithelial effects of aldosterone","volume":"5","author":"Stier","year":"1998","journal-title":"Curr Opin Endocrinol Diabet"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0215","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/01.RES.36.2.300","article-title":"Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: Role of renin and sodium in vascular changes","volume":"36","author":"Gavras","year":"1975","journal-title":"Circ Res"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0220","first-page":"H1454","article-title":"Resistance to mineralocorticoids in Wistar-Furth rats","volume":"272","author":"Ullian","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0225","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","article-title":"Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo","volume":"58","author":"Brown","year":"2000","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0230","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1161\/01.CIR.103.25.3062","article-title":"Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina","volume":"103","author":"Bogarty","year":"2001","journal-title":"Circulation"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0235","doi-asserted-by":"crossref","first-page":"F209","DOI":"10.1152\/ajprenal.00032.2002","article-title":"Plasminogen activator inhibitor-1 and the kidney","volume":"283","author":"Eddy","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0240","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/01.HYP.32.6.965","article-title":"Effect of activation and inhibition of the renin-angiotensin system of plasma PAI-1","volume":"32","author":"Brown","year":"1998","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0245","first-page":"336","article-title":"Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production","volume":"85","author":"Brown","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0250","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","article-title":"Local angiotensin II and transforming growth factor-\u03b21 in renal fibrosis in rats","volume":"35","author":"Sun","year":"2000","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0255","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0749-0704(05)70162-7","article-title":"Oxidants and antioxidant therapy","volume":"17","author":"Rotstein","year":"2001","journal-title":"Crit Care Clin"},{"issue":"Suppl","key":"10.1111\/j.1523-1755.2004.00701.x_bb0260","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1053\/ajkd.2001.27409","article-title":"Effect of chronic renal failure on nitric oxide metabolism","volume":"38","author":"Vaziri","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0922-4106(95)90018-7","article-title":"Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta","volume":"290","author":"Ikeda","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0270","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0735-1097(01)01657-6","article-title":"Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease","volume":"38","author":"Kuvin","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0275","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","article-title":"Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy","volume":"103","author":"Farquharson","year":"2002","journal-title":"Clin Sci"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0280","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0285","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00041552-200003000-00008","article-title":"Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension?","volume":"9","author":"Campese","year":"2000","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0290","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(88)90742-8","article-title":"Localisation of 11 beta-hydroxysteroid dehydrogenase\u2014Tissue specific protector of the mineralocorticoid receptor","volume":"29","author":"Edwards","year":"1988","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0295","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1126\/science.2845584","article-title":"Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated","volume":"242","author":"Funder","year":"1988","journal-title":"Science"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0300","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1161\/01.HYP.37.2.801","article-title":"Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension","volume":"37","author":"Quaschning","year":"2001","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0305","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/01.HYP.20.1.67","article-title":"Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses","volume":"20","author":"Ullian","year":"1992","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0310","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0039-128X(94)00016-6","article-title":"Aldosterone (ALDO) increases transmembrane influx of Na+ in vascular smooth muscle (VSM) cells through increased synthesis of Na+ channels","volume":"60","author":"Kornel","year":"1995","journal-title":"Steroids"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0315","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0320","doi-asserted-by":"crossref","first-page":"24316","DOI":"10.1016\/S0021-9258(19)51084-5","article-title":"Vascular aldosterone. Biosynthesis and a link to angiotensin II\u2013induced hypertrophy of vascular smooth muscle cells","volume":"269","author":"Hatakeyama","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0325","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentrations in chronic renal disease","volume":"21","author":"Hene","year":"1982","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0330","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0272-6386(99)70298-2","article-title":"Cardiovascular complications in patients with primary aldosteronism","volume":"33","author":"Nishimura","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0335","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0340","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2004.00701.x_bb0345","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00060793-200006000-00006","article-title":"Eplerenone, a new mineralocorticoid antagonist: In vitro and in vivo studies","volume":"7","author":"Funder","year":"2000","journal-title":"Curr Opin Endocrinol Diabetes"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381550001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381550001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T02:14:06Z","timestamp":1624414446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525381550001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S008525381550001X"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00701.x","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}